Amlodipine pharmacology
Pro Research Analysisby 
Searched over 200M research papers for "amlodipine pharmacology"
Amlodipine Pharmacology: Mechanism of Action and Drug Class
Amlodipine is a third-generation dihydropyridine calcium channel blocker. It works by inhibiting the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced blood pressure. Unlike earlier calcium antagonists, amlodipine has minimal effects on heart rate and myocardial contractility, making it effective for treating hypertension and angina pectoris with a low risk of reflex tachycardia or negative inotropic effects Abernethy1992Pa1994Burges1991+1 MORE.
Pharmacokinetics: Absorption, Distribution, Metabolism, and Elimination
Amlodipine is characterized by high oral bioavailability (60–80%) and is almost completely absorbed after oral administration. It has a slow rate of absorption, with peak plasma concentrations occurring 6–8 hours after dosing. The drug is highly water-soluble and photostable, and its strong affinity for cell membranes contributes to a large volume of distribution and a long elimination half-life of 34–60 hours. This allows for once-daily dosing and steady-state concentrations are typically reached within 1–1.5 weeks of regular use Abernethy1992Pa1994Abernethy1989+2 MORE.
Amlodipine is extensively metabolized in the liver, and hepatic excretion is the dominant route of elimination. In patients with liver disease, the elimination half-life is significantly prolonged, while renal dysfunction does not significantly affect its clearance. Food, digoxin, and cimetidine do not significantly alter amlodipine’s pharmacokinetics .
Pharmacodynamics: Blood Pressure and Vascular Effects
The gradual onset of action after oral administration results in a slow decrease in blood pressure over 4–8 hours, with effects lasting up to 24–72 hours after a single dose. This slow onset and long duration minimize fluctuations in blood pressure and reduce the risk of rebound hypertension upon discontinuation. During chronic therapy, blood pressure is consistently lowered with little variation throughout the 24-hour dosing interval Abernethy1992Pa1994Burges1991+1 MORE.
Special Populations: Elderly, Liver Disease, and Genetic Variability
In elderly patients, amlodipine’s elimination half-life is prolonged due to decreased clearance, leading to higher plasma concentrations and potentially greater blood pressure reduction at a given dose. However, after long-term use, the antihypertensive effect is similar between elderly and younger patients when adjusted for plasma concentration Abernethy1989Abernethy1990.
Genetic variations, particularly in the CYP2D6 and SLC22A1 genes, can affect amlodipine’s pharmacokinetics and safety. Poor metabolizers of CYP2D6 have a longer half-life and higher drug exposure, while certain SLC22A1 genotypes are associated with higher drug levels and increased risk of side effects like dizziness and thoracic pain .
Clinical Implications and Therapeutic Monitoring
Amlodipine’s unique pharmacokinetic profile—high bioavailability, slow absorption, and long half-life—makes it suitable for once-daily dosing and provides stable blood pressure control. Therapeutic drug monitoring may be useful in optimizing therapy, especially in patients with uncontrolled hypertension or those at risk for adverse effects due to genetic differences or liver impairment .
Additional Pharmacological Actions
Beyond its primary vasodilatory effect, amlodipine may have pleiotropic actions, such as modulating nitric oxide production, interacting with cholesterol and oxidants, and inhibiting smooth muscle cell proliferation. These ancillary effects may contribute to its benefits in vascular disease and ischemic heart disease Burges1991Mason2003. Network pharmacology studies also suggest that amlodipine acts through multiple pathways, including calcium signaling and neuroactive ligand-receptor interactions, which may be relevant in conditions like hypertension with chronic kidney disease .
Conclusion
Amlodipine stands out among calcium channel blockers for its high oral bioavailability, slow onset, long duration of action, and minimal cardiac side effects. Its pharmacokinetic and pharmacodynamic properties support its use as a first-line agent for hypertension and angina, with additional benefits in special populations and potential pleiotropic vascular effects. Genetic and hepatic factors should be considered to optimize safety and efficacy.
Sources and full results
Most relevant research papers on this topic